Study on Preliminary Safety and Efficacy of the ARC Therapy Using the ARC-IM Lumbar System to Support Mobility in People With Chronic Spinal Cord Injury (BoxSwitch)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorEcole Polytechnique Fédérale de Lausanne

About this trial

The purpose of this pre-market clinical study is to assess the preliminary safety and efficacy of the ARC Therapy using the ARC-IM Lumbar System at supporting mobility in participants who have previously received a spinal array and an implantable pulse generator (IPG) either through the STIMO protocol (NCT02936453) or similar studies conducted abroad. They will be proposed to exchange their currently implanted system with components of the newly developed ARC-IM Lumbar system. The goal is to improve more effective lower-limb motor activities, while also simplifying the personal at-home use of the system. In addition, this study aims to evaluate the potential effect of ARC Therapy on muscle tone, bladder, bowel and sexual functions, and quality of life of the participants.

Preliminary safety and efficacy will be assessed in both the short term and throughout the duration of the study (from the surgery to 36 months after the implantation of the ARC-IM Lumbar system).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Implanted with a spinal array (Specify 5-6-5 or Go2 Lead) for lower limb mobility, as confirmed by imaging, videos, or neurophysiology recordings.

Age 18-65

SCI graded as American Spinal Injury Association Impairment Scale (AIS) A, B, C & D

SCI ≥ 12months

Disqualifiers

Diseases and conditions that would increase the morbidity and mortality of spinal cord injury surgery

History of myocardial infarction or cerebrovascular event within the past 6 months

Limitation of walking function based on accompanying (CNS) disorders (systemic malignant disorders, cardiovascular disorders restricting physical training, peripheral nerve disorders)

Any active implanted cardiac device such as pacemaker or defibrillator

Trial design

Design model

Single group

Treatments tested in this trial

  • Procedure/Surgery

    Device

    The intervention involves the replacement of parts of the current implanted system with components of the ARC-IM Lumbar system.

Treatment groups

8 Participants
are divided into 1 treatment group
Group A: Targeted Epidural Spinal StimulationExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Preliminary safety of the ARC Therapy

Occurrence of Serious Adverse Events and Adverse Events that are deemed related or possibly related to the study procedure or to the ARC-IM system.

Time frame
Through study completion (expected 3 years)

Secondary outcomes

1

10 Meters Walk test (m/s)

The 10 Meters Walk Test is a performance measure used to assess walking speed in meters per second over a short distance.

Time frame
Baseline, Short-term (up to 6months), 12 months, 24 months and 36 months
2

6 Minutes Walk test (meters)

The 6 minutes walk test is a performance measureused to assess aerobic capacity and endurance.

Time frame
Baseline, Short-term (up to 6months), 12 months, 24 months and 36 months
3

International Standards For Neurological Classification of Spinal Injury (ISNCSCI)

A neurological assessment and classification of a spinal cord injury

Time frame
Baseline, 12 months, 24 months and 36 months
4

Spinal Cord Injury Functional Ambulation Inventory (SCI-FAI)

The SCI-FAI assesses functional walking ability in ambulatory individuals with SCI.

Time frame
Baseline, Short-term (up to 6months), 12 months, 24 months and 36 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Ecole Polytechnique Fédérale de Lausanne

Lead sponsor

Centre Hospitalier Universitaire Vaudois

Sponsor institution